On February 28, 2018 BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, reported that Russell Skibsted, Chief Financial Officer of BioTime, will be presenting at the Raymond James 39th Annual Institutional Investor Conference on Wednesday, March 7, 2018 at 10:25am ET, at the J.W. Marriott Grande Lakes Hotel (Press release, BioTime, FEB 28, 2018, View Source;p=RssLanding&cat=news&id=2335255 [SID1234524223]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Skibsted will also be meeting with investors throughout the conference. One-on-one meetings with Mr. Skibsted may be scheduled through the Raymond James 1×1 desk or by contacting David Nakasone, Director of Investor Relations at BioTime, at 510-871-4188 or [email protected].

About The Raymond James 39th Annual Institutional Investors Conference

The Institutional Investors Conference, held annually in Orlando, Florida during the first week of March, is Raymond James’ signature event. In 2017, the event featured over 300 companies and more than 900 institutional investors from the U.S., Canada and Europe.